We studied serum amylase and its isoenzymes prospectively in 163 consecutive asymptomatic patients, 149 men and 14 women, infected with HIV and attending an HIV out-patient clinic. Six patients were receiving dideoxyinosine (DOl), a drug known to cause pancreatitis. No patient, however, had clinical signs suggestive of pancreatitis.
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Gastrointestinal symptoms are common in patients with human immunodeficiency virus (HIV) infection and pancreatic lesions have been reported in up to 54% of patients with acquired immunodeficiency syndrome (AIDS) at autopsy.J " Lesions may be due to opportunistic infections (Cytomegalovirus, Cryptococcus, Toxoplasma gondii, Candida), tumours (Kaposi sarcoma, lymphoma) and cystosteatonecrosis. However, little is known about the incidence, characteristics and significance of hyperamylasaemia in asymptomatic patients infected with HIV. This information will be particularly useful as the proportion of HIV infected individuals using antiretroviral agents, such as dideoxyinosine (001), which may cause pancreatitis becomes increasingly widespead. Adverse effects of 001 include pancreatitis in 3-29% of patients treated." Frequent and repeated requests are made for serum amylase measurements in asymptomatic HIV patients attending the outpatient clinic. Hyperamylasaemia is a not uncommon finding. This study was designed to quantify the frequency of hyperamylasaemia Correspondence: Dr Ying Foo. prospectively in an outpatient group of HIV infected asymptomatic individuals, characterize the elevated amylase, and determine its significance in the context of HIV infection. We report here our findings on serum amylase and isoamylase in these patients. We also measured CD4 lymphocyte counts and serum immunoglobulins A, G and M in order to determine whether amylase changes were related to disease severity as indicated by CD4 counts or, for macroamlyase (immunoglobulin-bound amylase), to serum immunoglobulin alterations.
MATERIALS AND METHODS

Patients
In a prospective study, we investigated 163 consecutive asymptomatic patients infected with HIV; 149 men (age range from 19 to 66 years, median 42 years) and 14 women (age range from 21 to 40 years, median 29 years); attending an outpatient clinic over a 2 month period. The clinical data recorded included demographic details, clinical symptoms and signs, presence of any other documented infections and medications received up to I month prior to blood sampling. As part of a drug trial, six patients were on DDI but the drug was stopped at the time the sample was taken.
Blood samples were collected into Sarstedt gel tubes for routine biochemistry profile and serum amylase. The samples were centrifuged within 2 to 4 h of collection and assayed within 24 h. They were stored at 4°C until assay. Blood samples for CD4 lymphocyte count were collected in EDTA tubes.
Methods
Serum total amylase actrvity was measured at 37°C with an EPS-blocked PNP maltoheptaoside substrate (Boehringer Mannheim) on the Hitachi 747 analyser. Serum isoamylase examination was carried out on samples from patients with hyperamylasaemia (> 200 UjL) using electrophoretic separation on cellulose acetate followed by incubation with a chromogenic substrate (insoluble starch polymer crosslinked to Cibachron Blue F3G-A) and densitometric scanning of the stained fractions.' Pancreatic (P) and Salivary (S) fractions are clearly separated, macroamylase shows a streaked pattern in the globulin region. Serum immunoglobulins A, G and M were measured in patients with hyperamylasaemia using an immunoturbidimetric method (The Quant reagent, Boehringer Mannheim) on the Hitachi 911 analyser. The CD4 lymphocyte count was 700 600 .. . 
RESULTS
Serum total amylase activity was elevated in 39 of 163 (24%) asymptomatic HlV infected patients (Fig. I) . Activities ranged from 224 to 616 UjL (mean 306 UjL). Of these 39 patients, II (28%) had raised total amylase due to an increased pancreatic fraction, 17 (42%) due to increased salivary amylase and six (17%) due to both pancreatic and salivary isoenzyme increase.
In the remaining five patients (13%), increased total amylase was associated with macroamylase. In the six patients on DDI, two had raised total amylase due to increased salivary amylase, two due to increased pancreatic and salivary amylase and two had macromylase.
Of the 17 patients with a raised P fraction, one was known to drink alcohol to excess. Nine of the 17 patients took azothiaprine (AZT) and prophylactic low dose trimethoprime-sulphamethoxazole, and two used prophylactic nebulized pentamidine 300 mg fortnightly. There was no greater use of trimethoprirne-co-trirnoxazole, pentamidine or AZT in the patients with hyperamylasaemia compared to those with normal serum amylase.
The 39 asymptomatic HIV infected hyper-amy1asaemic patients comprised 23 patients with Center for Disease Control (CDC) stage IV, four with stage III and 12 with stage II disease, there was no difference in CD4 count for those with an elevated P (CD4 range 0--700 x 10~jL, mean 146 x 106jL) compared to those with a raised S fraction (CD4 range 0--500 x 106jL, mean 140 x 106jL). Macroamylasaemia occurred over a similar CD4 range 0--620 x 106jL although the mean CD4 was higher at 246 x 106jL.
The absolute CD4 lymphocyte count of these 39 patients was undetectable in eight and less than the lower reference limit in 25 patients. Six patients had CD4 lymphocyte count within the normal range.
Serum immunoglobulins were also measured in the 39 patients with raised amylase. Serum IgA was elevated in 13 of 39 patients (33%), IgG in 27 patients (69%) and IgM in nine patients (23%). Of the five patients with rnacroamylase, three had increased IgA, one had elevated IgA and IgG and the remaining patient had normal levels.
DISCUSSION
Awareness of a high frequency of pancreatic lesions (50-70%) in patients with AIDS initial1y arose from autopsy data.l-' Subsequent clinical studies's? confirmed an increased incidence of pancreatitis (31-46%). During these studies hypermyalasaemia occurring without pancreatitis was identified. However, the high incidence of hyperamylasaemia (54%) and pancreatitis (31%) in one study" is not representative of the population infected with HIV as it involved retrospective analysis of 39 patients with AIDS who had recorded serum amylase measurements in their notes and were therefore more likely to be ill. Macromylasaemia was not detected in the limited isoenzyme analyses performed in this group. A prospective study? of 94 symptomatic patients with AIDS-related complex (ARC) identified an 8% incidence of hyperamylasaemia. Again, limited isoamylase analysis on seven of these patients found five with elevated S or both Sand P fractions, two had macroamylase and none had an isolated P fraction.
Our results derived prospectively from a large group of HIV infected individuals showed that hyperamylasaemia is frequent (24%) in asymptomatic patients. Combining the groups with raised P isoamylase and elevated fractions of both P and S isoamylase, the total percentage of those with a raised P fraction in the hyperamylasaemia group was 45%. These measurements probably indicate the presence of mild, asymptomatic pancreatic disease, since none of our patients with pancreatic amylase elevation had clinical il1ness suggestive of pancreatitis. Alcohol was a possible aetiological agent for pancreatic disease for one patient. The remainder of the patients with an elevated P fraction had no obvious underlying cause at the time of blood sampling.
A significant proportion (42%) of our patients with hyperamylasaemia had an isolated elevation of the S fraction. Although no obvious salivary gland disease was apparent, xerostomia is not uncommon in advanced HIV disease. Salivary-type amylase may also derive from liver, intestine, skeletal muscle, urogenital epithelium and renal retention" the significance of its increase in our subjects is thus unclear.
The isoamylase findings in our patients on DDI confirm earlier similar work" which identified a heterogenous elevation of Sand P fractions. None of the DDI treated patients had a raised P fraction alone, and all six were withdrawn from the drug trial in which they had been participating on the basis of their elevated total amylase. We reiterate the need to perform isoamylase assays on those taking DDI or other drugs with potential pancreatic toxicity to confirm that any total amylase increase is, in fact, of pancreatic origin.
There was no association between disease severity as indicated by CD4 counts, and amylase changes in asymptomatic HIV patients, neither was there any difference between those with elevated P compared to those with a raised S fraction.
Ten of the 39 patients with elevated amylase were of African origin and one of Asian origin. These 11 patients had a combination of isolated S, isolated P and combined Sand P fractions. One published study has suggested that the reference range for healthy Asians and West Indians may be higher than for Caucasians." The possibility exists, therefore, that Africans may have a similarly elevated normal range, but this is yet to be confirmed.
Macroamylasaemia was first described in a patient with AIDS by Greenberg in 1987 10 and more recently in patients receiving DDI by Butler et al," Studies involving isoamylase assays in HIV infected individuals, as discussed above, have been very limited to date. Our results from a large group of patients indicate that macroamylasaemia is frequent (13%) in asymptomatic HIV patients. Macroamylasaemia occurs when normal circulating serum amylase, usually S type, binds to another serum molecule, usually an immunoglobulin to form a high molecular weight complex that is too large to excrete in the urine. It occurs in 1% of the hospital patient population and 2·5% of patients with hyperamylasaemia. It is of uncertain significance although it occurs more frequently in patients with abnormalities of humoral immunity and autoimmune disease. The elevations in serum IgG and IgA observed in this study are indicative of aberrant B cell activation with increased polyclonal immunoglobulin secretion typical1y seen in HIV infection. This may predispose these patients to macroamylase formation. Malabsorption syndromes and other inflammatory diseases of the gut are also associated with macroamylase production. Another mechanism for increased macroamylase formation may be that the enteropathies occurring in HIV infection may allow absorption of an increased antigenic load through altered gut permeability, with associated hypersecretion of IgA since in HIV patients often suffer a variety of gastrointestinal illnesses which may result in requests for serum amylase measurements. It is important to identify rnacroamylasaemia, a benign condition, as a cause of amylase increase, in order to prevent further unnecessary investigations for pancreatic disease.
In conclusion, to our knowledge, we have carried out the largest prospective study to date of a typical group of asymptomatic HIV infected individuals attending an HIV outpatient clinic. Our large sample is likely to be representative of the population of asymptomatic HIV infected individuals as a whole. Hyperamylasaemia was present in about one-quarter and was heterogenous, due to elevation of pancreatic or salivary fractions or both or macroamylase. Knowing the type of the isoenzyme may act as a useful guide to therapy with drugs potentially harmful to the pancreas. If subclinical pancreatic inflammation is detected by an elevated P fraction, such drugs can be avoided or their effects monitored more closely. Detection of an isolated S rather than the P fraction could prevent the discontinuation of 001 and other potentially useful pancreatoxic drugs. Similarly, the recognition of macroamylase as a frequent cause of hyperamylasaemia can assist with management by preventing unnecessary investigations for pancreatic disease.
